Send article
i

Todos los números de Acta Bioethica (desde 2000 a la fecha) están disponibles en formato PDF en los sitios:

Acta Bioethica

SciELO Chile

Validation of an instrument for the application of principled bioethical principles in clinical research protocols

Authors

Vol. 30 No. 1 (2024): TRANSHUMANISMO, INTELIGENCIA ARTIFICIAL Y BIOÉTICA

Abstract

The aim of this article is to report on the validation of an instrument on the application of principialist bioethical principles in each of the elements of clinical research protocols. To this end, a 173-item instrument was evaluated using the Delphi method, with the collaboration of 12 Latin American experts in research bioethics. The instrument underwent two rounds of revision. In the end there were only 171 items, in which the bioethical principles were applied 208 times, of which 87 (41.82%) belonged to Beneficence, 63 (30.29%) to Non-Maleficence, 36 (17.31%) to Justice and 22 (10.58%) to Autonomy. Regarding the congruence of the principles in general with respect to the variables of the elements of the clinical research protocol, it was found on 189 (90.87% CI 95% 86.10 to 94.41) occasions, K=0.98 (0.01), p=<0.0001. It is concluded that the validated instrument gives us the option of applying the bioethical principles of the principialist current to each of the elements of the clinical research protocols.

Keywords:

bioethical principles, clinical research, principialist

Downloads

How to Cite
Bustos Saldaña, R. ., & en Bioética de América Latina, G. de I. (2024). Validation of an instrument for the application of principled bioethical principles in clinical research protocols. Acta Bioethica, 30(1), pp. 95–105. Retrieved from https://revistainvi.uchile.cl/index.php/AB/article/view/74982
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Endnote/Zotero/Mendeley (RIS) BibTeX
 
Acta Bioethica
Centro Interdisciplinario de Estudios en Bioética
Universidad de Chile
DATOS DE INVESTIGACIÓN
Dirección de Servicios de Información y Bibliotecas (SISIB)